Vincenzo E. Chiuri
Francavilla Fontana, 72021, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Real-world Predictors of Early Mortality and Treatment Discontinuation in HCC Patients Treated with Atezolizumab-Bevacizumab.
Journal: Journal of gastrointestinal cancer
Published: December 11, 2025
Prognostic value of systemic inflammatory markers in avelumab maintenance for advanced urothelial carcinoma: the multicentric SAILOR analysis.
Journal: Scientific reports
Published: July 21, 2025
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience.
Journal: European urology oncology
Published: February 18, 2025
Corrigendum: The molecular tumor board as a step in cancer patient management: a southern Italian experience.
Journal: Frontiers in medicine
Published: October 14, 2024
Standard Versus Reduced CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: An Observational Multicenter Study.
Journal: Journal of clinical medicine
Published: October 08, 2024
Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study.
Journal: Cancers
Published: September 13, 2024
The molecular tumor board as a step in cancer patient management: a southern Italian experience.
Journal: Frontiers in medicine
Published: May 14, 2024
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care.
Journal: Prostate cancer and prostatic diseases
Published: July 29, 2023
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results.
Journal: The oncologist
Published: September 20, 2022
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.
Journal: The Lancet. Oncology
Published: April 12, 2022
First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry.
Journal: Tumori
Published: April 11, 2022
Last Updated: 09/26/2026